Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2020 · 10-Q
Revenue$15.29M$15.29M+37.7% vs Q2 2019 Net Income-$3.71M-$3.71MN/M vs Q2 2019 EPS Diluted-$0.06-$0.06N/M vs Q2 2019 Gross Profit$9,088,000+45.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,556,000N/M Free Cash Flowderived-$1,648,000N/M Margins · derivedGross margin59.4%+3.1 pt vs Q2 2019
Operating margin-24.1%+40.6 pt vs Q2 2019
Net margin-24.3%+45.6 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 6, 2020 · 37 d after period end